8 citations
,
April 2015 in “Expert Review of Gastroenterology & Hepatology” This review highlights the importance of promptly addressing symptoms in patients with inflammatory bowel disease, whether they stem from disease activity, medication side effects, or related autoimmune conditions, but it reports no new findings.
November 2025 in “Open Repository of the University of Porto (University of Porto)” This report covers an internship at a pharmacy and hospital where multiple pharmaceutical activities were examined, including the preparation of individualized medication and the comparison of drugs for hypercholesterolemia treatment.
This study reports the case of a 12-year-old girl who developed psoriatic alopecia after increasing her dose of the TNF-α inhibitor adalimumab for Crohn's disease, emphasizing psoriatic alopecia as a phenomenon associated with these medications.
February 2026 in “Cureus” In this narrative review, the authors compared monotherapy and combination therapy for type 2 diabetes, finding that while monotherapy is effective in early stages, combination therapy offers superior glycemic control and cardiovascular benefits, though it requires individualized selection for safety and adherence.
December 2025 in “npj Breast Cancer” In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.
3 citations
,
November 2025 in “Annals of Medicine” This study found that higher adherence to healthy dietary patterns such as DASH, AHEI, and MED significantly reduced all-cause mortality in hypertensive patients, with the DASH diet particularly lowering cardiovascular mortality, highlighting diet's role in hypertension management.
February 2019 in “Urology” This study observed that the out-of-pocket prices for generic medications used to treat benign prostatic hyperplasia can vary by up to 500% among pharmacies in the Pittsburgh area, with chain pharmacies pricing significantly higher than independents.
July 2025 in “Journal of Investigative Dermatology” Spironolactone can safely lower blood pressure in patients on other blood pressure medications, but may slightly increase the risk of low blood pressure.
February 2024 in “Skin Research and Technology” This study found that combining scalp repair serum microneedles with oral and topical medications significantly improved hair regrowth in patients with moderate to severe androgenetic alopecia.
This study detected insomnia risk signals associated with various medications, primarily nervous system drugs, using the FDA's Adverse Event Reporting System data from 2004 to 2024.
November 2010 in “Clin-Alert” Monitoring for adverse effects in clinical treatments is crucial.
26 citations
,
December 2023 in “Prostate International” This review provides an overview of the risks and side effects associated with common medications used to treat benign prostatic hyperplasia, highlighting the importance for clinicians and patients to discuss these aspects for informed decision-making.
This study utilized the USFDA AERS to identify significant associations between various medications—such as anti-osteoporotic drugs and phenytoin—and gingival disorders, noting emergent signals with finasteride, COVID-19 vaccine, and levothyroxine, suggesting a need for awareness of oral side effects.
4 citations
,
March 2025 in “Journal of Cosmetic Dermatology” This study highlights a potential association between semaglutide, a diabetes medication, and increased reports of hair loss, with researchers calling for more rigorous clinical trials to confirm and better understand the risk.
September 2025 in “JMIR Dermatology” This narrative review reported that direct-to-consumer teledermatology improves access to care, adherence, and patient satisfaction for treating male androgenetic alopecia, but may lead to higher drug costs.
November 2017 in “JAMA internal medicine” Women also use 5α-reductase inhibitors, and their effects differ from men.
1 citations
,
November 2013 in “Pediatrics in Review” This article reviews the management and treatment of acne vulgaris, emphasizing patient education and adherence, but reports no new clinical results; the authors stress the need for individualized therapy.
December 2022 in “OBG Management” The conclusion is to diagnose PCOS with just hyperandrogenism and irregular periods, and treat with lifestyle changes and basic medications.
20 citations
,
March 2017 in “Arthritis research & therapy” In this study, researchers analyzed social media data to assess the comparative safety of arthritis medications, finding increased odds of herpes zoster and perforated bowel with certain therapies. Social media posts expressed more safety concerns than favorable opinions about drug safety.
13 citations
,
October 2023 in “Pharmaceutics” This study found that an intranasal gel containing risperidone-loaded glycethosomes significantly enhanced drug bioavailability and improved neuroprotective, antioxidant, and anti-inflammatory effects in schizophrenia-induced rats compared to oral therapies, suggesting a promising alternative for schizophrenic patients who struggle with adhering to oral medication.
8 citations
,
December 2008 in “Journal of The American Academy of Dermatology” This case report describes the first known instance of fixed drug eruption linked to finasteride, confirmed through an oral challenge test that reproduced symptoms at the same skin site.
4 citations
,
May 2018 in “Journal of Neuro-Ophthalmology” This review describes the evolution of treatments for relapsing multiple sclerosis, highlighting that while newer potent monoclonal agents can potentially achieve disease remission, they also pose moderate to severe adverse event risks that healthcare providers must understand.
1 citations
,
October 2013 in “Actas Dermo-Sifiliográficas” This review discusses the current role and challenges of compounding in dermatology without presenting new research results; the authors suggest its resurgence in practice despite pharmaceutical alternatives.
June 2026 in “Journal of Cosmetic Dermatology” In this study, digital treatment for androgenetic alopecia over six months led to significant improvements in quality of life among Brazilian men, particularly for those with consistent program adherence, although the absence of an in-person comparator limits causal conclusions.
January 2026 in “Figshare” In this case report, the researchers documented two instances of melasma linked to finasteride use, highlighting the need for clinicians to review medication history when treating facial hyperpigmentation, especially in individuals with darker skin types.
October 2025 in “International Journal of Molecular Sciences” This study found that topical rebamipide, originally a gastric ulcer medication, can activate hair follicle stem cells and promote hair regeneration by modulating dermal adipocyte metabolism, with potential targeting of the prostaglandin E receptor EP4.
In this retrospective study of 133 pediatric patients, topical minoxidil was generally well tolerated for managing androgenetic alopecia, but close monitoring and adherence to treatment, accounting for hormonal and concurrent conditions, were emphasized for effective care.
May 2024 in “Journal of cosmetic dermatology” This study found that topical finasteride mixed with minoxidil improved hair appearance and self-esteem in men with androgenetic alopecia, but it was not superior to oral finasteride and had lower treatment adherence.
Use the least toxic, most specific treatments for skin diseases, considering side effects and individual patient needs.
July 2012 in “Alzheimer s & Dementia” This case report describes a 57-year-old Navy veteran with mild cognitive impairment who showed cognitive improvement and reported better mood after CPAP treatment and medication adjustments.